The herbivenom known as Japonica is commonly used as a dietary supplement and herbal medicine.
It can also be used to treat severe, life-threatening conditions such as malaria, and can also help you sleep.
But the company that makes it, Juniper, has been accused of using the drug to make its products more expensive, with prices at around £50 to £200 per dose.
And with so many other medicinal products on the market, what do we know about how the drug affects the body?
Juniper has confirmed it has a relationship with Merck, and that it has tested the drug on its own patients.
But the company says it is not involved in the Merck-Merck drug trials.
The drug is manufactured in Germany by a company called GmbH, which has an established relationship with the pharmaceutical giant Pfizer.
Juniper says it has been working with Gmbh for over two years, but has no involvement with the Pfizer Pfizer Merck trials.
A spokesperson for Pfizer said:”We do not work with any company on clinical trials or clinical trials for other products.
The drug has never been tested on our own patients.”
The spokesperson said they do not have a relationship “with any company” on clinical trial trials.
In a statement, Junosource said it had been “partnering with Pfizer in the early phases of a clinical trial on the Japonic Acid (JAA) pill, which we hope will be completed in early 2019.”
“As with all pharmaceutical products, our clinical trials must be approved by the relevant regulatory authority and we are cooperating fully with them,” it said.
The spokesperson added: “We have been cooperating with the FDA since the beginning of this process.”
The drug was originally approved by regulators in 2014 to treat serious and life-defining conditions including malaria, hepatitis B, and cancer.
The new research is the latest in a series of anti-cancer treatments being tested on human patients in a bid to get them on track to being able to treat cancer.